ADC (antibody-drug conjugate) drugs are composed of monoclonal antibodies, linkers and active drugs. It conjugates monoclonal antibodies to specific antigens on tumor cells to deliver cytotoxic drugs to tumor lesions. Compared with traditional chemical drugs and biological drugs, ADCs significantly improved safety and efficacy. To date, a total of 15 ADC drugs have been approved worldwide (excluding ADC bioanalogues), involving 11 targets, including solid tumors and hematoma indications.

PEG and ADC Linker

Polyethylene glycol (PEG) is one of the most widely used linkers in targeted therapy. The right Linker helps maintain the stability between the antibody and the drug and helps the antibody selectively deliver the drug to the tumor cell and accurately release the drug. PEG linkers have the characteristics of high utilization rate, strong targeting and PH adjustment.

The ADC drug development track is hot, and many large companies at home and abroad have joined its ranks. Its market space is huge. It is expected that the quantity and quality of ADCs will increase significantly in the next ten years. “Biopharma PEG will focus on the research and development of ADC-Linker and continue to help the development of your research and development projects”, said the R&D director of Biopharma PEG.

ADC drugs Used PEG Linker

Biopharma PEG offers a variety of PEG linkers to facilitate antibody-drug conjugate (ADC) development projects. The purity of all PEG linkers are 95% above and they are the basic building blocks for a successful ADC. Two of the latest approved ADCs drugs, Trodelvy and Zynlonta, were developed with PEG moiety as part of their linker technology to improve solubility and in vivo stability.

1. Sacituzumab-govitecan (IMMU-132)

In May 2021, China's CFDA approved goxatuzumab (Trodelvy®, sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have previously received at least 2 systemic therapies or at least 1 of which has been used for metastatic disease. Sacituzumab-govitecan (IMMU-132) was conjugated to SN-38 via a cleavable maleimide linker with a short PEGylation unit.

2. Zynlonta

The FDA approved Zynlonta, a drug targeting CD19 developed by ADC Therapeutics, for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), including patients who have received stem cell transplantation and CAR-T cell therapy.

ADC drugs have emerged in an endless stream in recent years. The selection of antibodies, linkers, small molecule toxins, and the design of conjugation methods continue to promote the optimization of ADC drugs, which not only expands the therapeutic window, but also creates differentiated competition among ADC drugs. As a professional PEG derivatives supplier, Biopharma PEG is dedicated to being your most reliable partner to provide high-quality PEG linkers for your ADC discovery and development projects. 

Featured PEG linkers for ADCs : 

2-((Azido-PEG8-carbamoyl)methoxy)acetic acid | CAS NO. 846549-37-9 >>> 

mPEG36-NH2 | CAS NO. 32130-27-1  >>> 

N3-PEG3-NHS ester | CAS NO. 1245718-89-1  >>> 

NH2-PEG24-COOH | CAS NO. 196936-04-6  >>>